Harry Relouw

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.

Rhein Biotech NV developed and manufactured pharmaceutical drugs and vaccines. The company provided licenses to vaccines and biopharmaceutical products in the area of respiratory travel and hepatitis B/pediatric. Rhein Biotech was headquartered in Maastricht, the Netherlands.

Basic Pharma Holding BV develops, manufactures, and distributes pharmaceutical products and forms. It offers registered and investigational medicinal products and products by route of administration. It also provides process and product development, quality assurance, regulatory, pharmacovigilance, clinical trial, and laboratory services. The company was founded by Bob Kool and Jacques Havermans in 2003 and is headquartered in Geleen, the Netherlands.

Matisse Pharmaceuticals BV engages in the development of therapeutic product for the treatment of sepsis. It offers The company was founded in 2014 and is headquartered in Geleen the Netherlands.